Generated by AI
Denali Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing medicines for serious neurodegenerative and lysosomal storage diseases. Denali Therapeutics advances a portfolio of therapeutic programs aimed at conditions such as Alzheimer's disease, Parkinson's disease, and other rare neurological disorders. The company’s approach centers on delivering biologic and genetic medicines across the blood-brain barrier through its proprietary TransportVehicle platform, which is designed to improve access to hard-to-reach tissues in the central nervous system. Denali Therapeutics also works on product candidates across enzyme, oligonucleotide, and antibody-based programs, supporting a broader pipeline that targets both brain and body diseases. Headquartered in South San Francisco, California, Denali Therapeutics operates within the biotechnology sector and plays a role in the development of next-generation therapies for complex, high-unmet-need conditions.
Website161 Oyster Point Boulevard
South San Francisco, CA, 94080
United States
The latest articles about DNLI.
Analyst rates Denali (DNLI) stock a Buy. Avlayah's $17.8 million Q3 sales validate its platform, and Q4 guidance of $30-$32 million implies 65%+ sequential growth.
Summary of Jun 27's posts. Generated by AI.
No summary yet.
Summary of Mar 25's posts. Generated by AI.
Summary of Jun 27's posts. Generated by AI.
Investors talking about DNLI also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.